Development of a New Structural Class of Broadly Acting HCV Non‐Nucleoside Inhibitors Leading to the Discovery of MK‐8876-Reference-Cited by-同舟云学术

Development of a New Structural Class of Broadly Acting HCV Non‐Nucleoside Inhibitors Leading to the Discovery of MK‐8876

Published:2017-07-25 Issue:17 Volume:12 Page:1436-1448
ISSN:1860-7179
Container-title:ChemMedChem
language:en
Short-container-title:ChemMedChem

Author:

McComas Casey C.¹²^ORCID,Palani Anandan¹²,Chang Wei³,Holloway M. Katharine¹²,Lesburg Charles A.¹²,Li Peng³,Liverton Nigel¹²,Meinke Peter T.¹²,Olsen David B.¹²,Peng Xuanjia³,Soll Richard M.³,Ummat Ajay¹²,Wu Jie³,Wu Jin¹²,Zorn Nicolas¹²,Ludmerer Steven W.¹²

Affiliation:

1. Merck & Co. Inc. Kenilworth NJ USA

2. Present address: International Discovery Service UnitWuXi AppTec, Inc. 1690 Sumneytown Pike, Suite 150 Lansdale PA 19446 USA

3. WuXi AppTec Shanghai China

Publisher

Wiley

Subject

Organic Chemistry,General Pharmacology, Toxicology and Pharmaceutics,Molecular Medicine,Drug Discovery,Biochemistry,Pharmacology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/cmdc.201700228

Reference36 articles.

1. Evolving epidemiology of hepatitis C virus